Drug-eluting stents: Is it the beginning of the end for coronary artery bypass surgery?

Chinese Medical Journal

Volumn 117, Issue 9, 2004, Pages 1377-1387

  Raja, Shahzad G ^a  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

Coronary arteriosclerosis; Drug eluting stents; Percutaneous coronary interventions

Indexed keywords

ALBUMIN; ANGIOPEPTIN; ANTICOAGULANT AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; BATIMASTAT; CALCIUM CHANNEL BLOCKING AGENT; CELLULOSE; DACTINOMYCIN; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; FIBRIN; HALOFUGINONE; HYPOCHOLESTEROLEMIC AGENT; METHACRYLIC ACID; METHOTREXATE; PACLITAXEL; PHOSPHORYLCHOLINE; POLYETHYLENE; POLYMER; PROSTACYCLIN; PYROLYTIC CARBON; RAPAMYCIN; TACROLIMUS; TRANILAST; UNINDEXED DRUG; VASCULOTROPIN; VINCRISTINE; VINYL ACETATE;

ARTICLE; BRACHYTHERAPY; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY STENT; DEVICE; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG MECHANISM; HUMAN; MATERIAL COATING; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; CORONARY DISEASE; DRUG DELIVERY SYSTEMS; ESTRADIOL; HUMANS; PACLITAXEL; SIROLIMUS; STENTS; TACROLIMUS;

EID: 4844226476     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. O'Neill WW, Grines CL. Surgery or stent? The gap continues to narrow. Lancet 2002;360:961-962.
2. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary bypass graft surgery on survival: overview of 10-year results from randomised trials by the coronary artery bypass graft surgery trialists collaboration. Lancet 1994;344:563-570.
3. Davies RF, Goldberg AD, Forman S, et al. Asymptomatic cardiac ischemia pilot (ACIP) study two year follow up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 1997;95:2037-2043.
4. Pocock SJ, Henderson RA, Rickards AF, et al. Meta-analysis of randomized trials comparing coronary angioplasty with bypass surgery. Lancet 1995;346:1184-1189.
5. The bypass angioplasty revascularization investigation (BARI) investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217-225.
6. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of stenting with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-495.
7. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
8. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-1124.
9. Rodriguez A, Bernardi V, Navia J, et al. Argentine randomized study: coronary angioplasty with stenting versus coronary surgery in patients with multivessel disease (ERACI II): 30 day and one year follow up results. ERACI II investigators. J Am Coll Cardiol 2001;37:51-58.
10. Sigwart U, Stables RH, Booth J, et al. Coronary artery bypass surgery versus coronary intervention with stenting in patients with multivessel disease (stent or surgery trial): a randomized controlled trial. Lancet 2002;360:965-970.
11. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701-706.
12. Donners MM, Daemen MJ, Cleutjens KB, et al. Inflammation and restenosis: implications for therapy. Ann Med 2003;35:523-531.
13. Rajagopal V, Rockson SG. Coronary restenosis: a review of mechanisms and management. Am J Med 2003;115:547-553.
14. Degertekin M, Saia F, Lemus PA, et al. Sirolimus-eluting stents for the treatment of in-stent restenosis. Minerva Cardioangiol 2003;51:475-484.
15. Jochem J, Wodniecki J. Pathological mechanisms of coronary in-stent restenosis. Pol Arch Med Wewn 1999;102:905-909.
16. Ferns GA, Avades TY. The mechanisms of coronary restenosis: insights from experimental models. Int J Exp Pathol 2000;81:63-88.
17. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001; 344:250-256.
18. Waksman R, Raizner AE, Yeung AC, et al. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet 2002;359:551-557.
19. Grise MA, Massullo V, Jani S, et al. Five-year clinical follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation 2002;105:2737-2740.
20. Lansky AJ, Popma JJ, Colombo A. Follow-up angiographic comparison of the low dose vs high dose phosphorous-32 radioactive isostent: results from expanded IRIS and Milan Dose A Studies. J Am Coll Cardiol 1999;33:17A.
21. Costa MA, Sabat M, van der Giessen WJ, et al. Late coronary occlusion after intracoronary brachytherapy. Circulation 1999;100:789-792.
22. Kereiakes DJ. Hippocrates revisited: the evidence for drug-eluting stents. Circulation 2003;107:3012-3014.
23. Granada JF, Kaluza GL, Raizner A. Drug-eluting stents for cardiovascular disorders. Curr Atheroscler Rep 2003;5:308-316.
24. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part I. Circulation 2003; 107:2274-2279.
25. Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis: fact, fancy, and future. Circulation 1994;90:2070-2084.
26. Curfman GD. Sirolimus-eluting coronary stents. N Engl J Med 2002;346:1770-1771.
27. Schwartz RS, Edelman ER, Carter A, et al. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation 2002;106:1867-1873.
28. Whelan DM, van Beusekom HM, van der Giessen WJ. Mechanisms of drug loading and release kinetics. Semin Interv Cardiol 1998;3:127-131.
29. Costa MA. Drug-coated stents for restenosis. In: Faxon DP, ed. Restenosis: a therapeutic guide. London: Martin Dunitz; 2001:113-129.
30. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690-1697.
31. Lovich MA, Creel C, Hong K, et al. Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. J Pharm Sci 2001;90:1324-1335.
32. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 1998;98:82-89.
33. Morice MC, Serruys P, Constantini C, et al. Two-year follow-up of the RAVEL study: a randomized study with the sirolimus-eluting Bx-VELOCITY stent in the treatment of patients with de-novo native coronary artery lesions. J Am Coll Cardiol 2003;41:32A.
34. Holmes DR, Leon MB, Moses JW, et al. One year follow up of the SIRIUS study: a randomized study with the sirolimus-eluting Bx-VELOCITY in the treatment of patients with de-novo native coronary artery lesions. J Am Coll Cardiol 2003;41:32A.
35. Abizaid AA, Munoz JS, Seixas AC, et al. Is there any arterial toxic effect after overlapping sirolimus-eluting stents? J Am Coll Cardiol 2003;41:13A.
36. Ako J, Morino Y, Honda Y, et al. Late incomplete stent apposition following sirolimus eluting stent: serial quantitative intravascular ultrasound analysis from the SIRIUS trial. J Am Coll Cardiol 2003;41:33A.
37. Leon MB, Moses JW, Weisz G, et al. The frequency and consequences of angiographic aneurysms after sirolimus-eluting stents: results from SIRIUS. J Am Coll Cardiol 2003;41:13A.
38. Leon MB, Popma JJ, Yakubov S, et al. The effects of sirolimus-eluting stents on in-stent and peri-stent restenosis: an angiographic subanalysis from the SIRIUS trial. J Am Coll Cardiol 2003;41:14A.
39. SoRelle R. QTc interval and B-type natriuretic peptide levels predict death in patients with advanced heart failure. Circulation 2003;107:e9024-e9032.
40. Saia F, Lemos PA, Degertekin M, et al. Sirolimus-eluting stents for treatment of in-stent restenosis in the real world: preliminary results from the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol. 2003;41:53A.
41. Lee CH, Lemos PA, van Domburg RT, et al. Safety and efficacy of sirolimus-eluting stent (Cypher) in acute myocardial infarction: a substudy of the rapamycin-eluting stent evaluation at Rotterdam cardiology hospital (RESEARCH) study. J Am Coll Cardiol 2003;41:21A.
42. Regar E, Lemos PA, Lee CH, et al. Subacute stent thrombosis after sirolimus-eluting stent implantation in daily practice; results from the rapamycin eluting-stent evaluated at Rotterdam Hospital (RESEARCH) registry. J Am Coll Cardiol. 2003;41:23A.
43. Tanabe K, Lemos PA, Lee CH, et al. The impact of sirolimus-eluting stents on the outcome of patients with bifurcation lesions. J Am Coll Cardiol 2003;41:12A.
44. Airoldi F, Spanos V, Stankovic G, et al. Bifurcational coronary artery lesion treatment with rapamycin-eluting stents: results from a single center experience. J Am Coll Cardiol 2003;41:53A.
45. Colombo A, Louvard Y, Raghu C, et al. Sirolimus-eluting stents in bifurcation lesions: six-month angiographic results according to the implantation technique. J Am Coll Cardiol 2003;41:53A.
46. Costa MA, Moses JW, Leon MB, et al. Sirolimus-eluting stent for the treatment of bypass graft disease: the initial US experience. J Am Coll Cardiol 2003;41:13A.
47. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-794.
48. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six-and twelve-month results from a randomized, double blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
49. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003; 348:1537-1545.
50. Silber S. Paclitaxel-eluting stents: are they all equal? An analysis of six randomized controlled trials in de novo lesions of 3,319 patients. J Interv Cardiol 2003;16:485-490.
51. Kar S, Honda T, Mcclean D, et al. Elution of everolimus and sirolimus from a biodegradable polymer coated stent inhibits neointimal hyperplasia without inflammation or toxicity. J Am Coll Cardiol 2003;41:6A.
52. Grube E, Buellesfeld L, Mueller R, et al. First human experience using a new everolimus stent coating: procedural and 6-month follow-up results of the FUTURE trial. J Am Coll Cardiol 2003;41:6A.
53. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001; 104:2007-2011.
54. Gerckens U, Buellesfeld L, Horskotte D, et al. Evaluation of a tacrolimus-eluting coronary stent with nanoporous ceramic coating in treatment of native coronary artery lesions: phase I and II of the PRESENT study. J Am Coll Cardiol 2003;41:7A.
55. Smith EJ, Rothman MT. Antiproliferative coatings for the treatment of coronary heart disease: what are the targets and which are the tools? J Interv Cardiol 2003;16:475-483.
56. Abizaid AA, New G, Abizaid AS, et al. First clinical experience with 17-estradiol-eluting BiodivYsio matrix LO stent to prevent restenosis in de-novo native coronary arteries: six-month clinical outcomes and angiographic follow-up from the EASTER trial. J Am Coll Cardiol 2003;41:56A.
57. Costa MA, Sousa JEM, Abizaid AA, et al. Three-dimensional intravascular ultrasound assessment after the implantation of estrogen-eluting PC-coated stents in human coronary arteries. J Am Coll Cardiol 2003;41:5A.
58. Airoldi F, DiMario C, Stankovic, et al. Estradiol eluting stents for the prevention of restenosis in native coronary arteries: results from the randomized multicentric study EASTER. J Am Coll Cardiol 2003;41:56A.
59. Berrocal DH, Gonzalez GE, Morales C, et al. Local delivery of irinotecan with drug-eluting stents inhibits neointimal proliferation in hypercholesterolemic rabbits. J Am Coll Cardiol 2003;41:16A.
60. Kwok OH, Chow WH, Lee CH, et al. First-in-human study of angiopeptin-eluting stents: a quantitative coronary angiography and volumetric intravascular ultrasound study. J Am Coll Cardiol 2003;41:6A.
61. Schuhlen H, Kastrati A, Mehili J, et al. Evaluation of the BiodivYsio stent with matrix HI coating designed for local drug delivery in coronary arteries: a randomized trial. J Am Coll Cardiol 2003;41:7A.
62. Boland JL, Corbeij HA, van der Giessen W, et al. Multicenter evaluation of the phosphorylcholine-coated biodivYsio stent in short de novo coronary lesions: The SOPHOS study. Int J Cardiovasc Inter-vent 2000;3:215-225.
63. Carter AJ, Welch L, Gibson L, et al. Stents coated with the lipophilic compound A24 (ABT-578) profoundly inhibit neointimal formation in the porcine coronary model. J Am Coll Cardiol 2003;41:6A.
64. Caussin C, Alibelli MJ, Elbaz M, et al. Titanium nitride-oxide coated stent: six-month angiographic and intravascular ultrasound follow-up. J Am Coll Cardiol 2003;41:7A.
65. Hou D, Narciso H, Kamdar K, et al. Reducing neointimal proliferation by a stent-based delivery of nitric oxide in a porcine carotid overstretch injury model. J Am Coll Cardiol 2003;41:6A.
66. Kim W, Jeong MH, Cha GS, et al. The effect of carvedilol-loaded BiodivYsio stent on neointimal hyperplasia in a porcine coronary stent restenosis model. J Am Coll Cardiol 2003;41:31A.
67. Jaschke B, Wegener F, Wessely R. Application of synthetic CDK inhibition (flavopiridol) as a novel therapeutic strategy to effectively limit common pathways of in-stent restenosis: characterization of molecular effects and applicability on drug coated stents. J Am Coll Cardiol 2003;41:31A.
68. Mack MJ, Duhaylongsod FG. Through the open door! Where has the ride taken us? J Thorac Cardiovasc Surg 2002;124:655-659.
69. Hiatt BL, Ikeno F, Yeung AC, et al. Drug-eluting stents for the prevention of restenosis: in quest for the Holy Grail. Catheter Cardiovasc Interv 2002;55:409-417.
70. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
71. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
72. Presbitero P, Asioli M. Drug-eluting stents do they make the difference? Minerva Cardioangiol 2002;50:431-442.
73. Tanabe K, Serruys PW, Grube E, et al. TAXUS III trial: instent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003;107:559-564.
74. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus drug-eluting stents for the treatment of complex coronary stenoses: results from the randomized SIRIUS trial. J Am Coll Cardiol 2003;41:32A.
75. Virmani R, Kolodgie FD, Farb A, et al. Drug-eluting stents: are human and animal studies comparable? Heart 2003;89:133-138.
76. Walpoth BH, Pavlicek M, Celik B, et al. Prevention of neointimal proliferation by immunosuppression in synthetic vascular grafts. Eur J Cardiothorac Surg 2001;19:487-492.
77. Virmani R, Liistro F, Stankovic G, et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 2002;106:2649-2651.